Literature DB >> 29954925

Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension.

Grayson L Baird1, Christine Archer-Chicko2, R Graham Barr3, David A Bluemke4, Andrew E Foderaro1, Jason S Fritz2, Nicholas S Hill5, Steven M Kawut2,6,7, James R Klinger1, Joao A C Lima8, Christopher J Mullin1, Pamela Ouyang8, Harold I Palevsky2, Amy J Palmisicano1, Diane Pinder2, Ioana R Preston5, Kari E Roberts5, K Akaya Smith2,7, Thomas Walsh1, Mary Whittenhall1, Corey E Ventetuolo1,9.   

Abstract

High oestradiol (E2) and low dehydroepiandrosterone-sulfate (DHEA-S) levels are risk factors for pulmonary arterial hypertension (PAH) in men, but whether sex hormones are related to PAH in women is unknown.Post-menopausal women aged ≥55 years with PAH were matched by age and body mass index to women without cardiovascular disease. Plasma sex hormone levels were measured by immunoassay.Lower levels of DHEA-S (p<0.001) and higher levels of E2 (p=0.02) were associated with PAH. In PAH cases (n=112), lower DHEA-S levels were associated with worse haemodynamics (all p<0.01) and more right ventricular dilatation and dysfunction (both p=0.001). Lower DHEA-S levels were associated with shorter 6-min walking distance (6MWD) (p=0.01) and worse functional class (p=0.004). Each Ln(1 µg·dL-1) decrease in DHEA-S was associated with a doubling in the risk of death (hazard ratio 2.0, 95% CI 1.5-2.7; p<0.001). Higher levels of E2 were associated with shorter 6MWD (p=0.03) and worse functional class (p=0.01).High E2 and low DHEA-S levels are associated with the risk and severity of PAH in post-menopausal women. Hormonal modulation should be studied as a treatment strategy in PAH.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29954925      PMCID: PMC6469347          DOI: 10.1183/13993003.00467-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

Review 1.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

2.  Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.

Authors:  Aline C Oliveira; Chunhua Fu; Yuanqing Lu; Mason A Williams; Liya Pi; Mark L Brantly; Corey E Ventetuolo; Mohan K Raizada; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-07-31       Impact factor: 5.464

3.  Fulvestrant for the Treatment of Pulmonary Arterial Hypertension.

Authors:  Steven M Kawut; Diane Pinder; Nadine Al-Naamani; Amber McCormick; Harold I Palevsky; Jason Fritz; K Akaya Smith; Jeremy A Mazurek; Margaret F Doyle; Margaret R MacLean; Angela DeMichele; David A Mankoff
Journal:  Ann Am Thorac Soc       Date:  2019-11

Review 4.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

5.  Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension.

Authors:  Grayson L Baird; Thomas Walsh; Jason Aliotta; Melissa Allahua; Ruth Andrew; Ghada Bourjeily; Alexander S Brodsky; Nina Denver; Mark Dooner; Elizabeth O Harrington; James R Klinger; Margaret R MacLean; Christopher J Mullin; Mandy Pereira; Athena Poppas; Mary Whittenhall; Corey E Ventetuolo
Journal:  Ann Am Thorac Soc       Date:  2021-02

6.  Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).

Authors:  Michael B Fallon; Steven M Kawut; Nadine Al-Naamani; Michael J Krowka; Kimberly A Forde; Karen L Krok; Rui Feng; Gustavo A Heresi; Raed A Dweik; Sonja Bartolome; Todd M Bull; Kari E Roberts; Eric D Austin; Anna R Hemnes; Mamta J Patel; Jae K Oh; Grace Lin; Margaret F Doyle; Nina Denver; Ruth Andrew; Margaret R MacLean
Journal:  Hepatology       Date:  2020-09-29       Impact factor: 17.425

Review 7.  Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop.

Authors:  Jane A Leopold; Steven M Kawut; Micheala A Aldred; Stephen L Archer; Ray L Benza; Michael R Bristow; Evan L Brittain; Naomi Chesler; Frances S DeMan; Serpil C Erzurum; Mark T Gladwin; Paul M Hassoun; Anna R Hemnes; Tim Lahm; Joao A C Lima; Joseph Loscalzo; Bradley A Maron; Laura Mercer Rosa; John H Newman; Susan Redline; Stuart Rich; Franz Rischard; Lissa Sugeng; W H Wilson Tang; Ryan J Tedford; Emily J Tsai; Corey E Ventetuolo; YouYang Zhou; Neil R Aggarwal; Lei Xiao
Journal:  Circ Heart Fail       Date:  2021-06-15       Impact factor: 10.447

8.  Influence of 2-Methoxyestradiol and Sex on Hypoxia-Induced Pulmonary Hypertension and Hypoxia-Inducible Factor-1-α.

Authors:  Craig K Docherty; Margaret Nilsen; Margaret R MacLean
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

9.  Experimental design of the Effects of Dehydroepiandrosterone in Pulmonary Hypertension (EDIPHY) trial.

Authors:  Thomas P Walsh; Grayson L Baird; Michael K Atalay; Saurabh Agarwal; Daniel Arcuri; James R Klinger; Christopher J Mullin; Heather Morreo; Brynn Normandin; Sruti Shiva; Mary Whittenhall; Corey E Ventetuolo
Journal:  Pulm Circ       Date:  2021-05-21       Impact factor: 3.017

10.  Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling.

Authors:  Chunhua Fu; Yuanqing Lu; Mason A Williams; Mark L Brantly; Corey E Ventetuolo; Laurence M Morel; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Br J Pharmacol       Date:  2020-02-04       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.